KOD - Why Kodiak Sciences Stock Is Sharply Lower Today
Shares of the clinical-stage eye disease specialist Kodiak Sciences (NASDAQ: KOD) are trending lower on higher-than-normal volume today. Specifically, the biotech's stock price fell by as much as 10% in early morning action on Tuesday, and it was still down by a noteworthy 8.8% as of 10:52 a.m. ET.
By contrast, the morning session has so far been a fairly good outing for biotech stocks at large. The SPDR S&P Biotech ETF , for instance, was up by a respectable 2.26% at the time of this writing.
Kodiak's stock is under pressure this morning in response to a downgrade from an analyst at Citigroup . The analyst, Neena Bitritto-Garg, downgraded the biotech's stock to sell from neutral. Bitritto-Garg is concerned about the prospects of Kodiak's ongoing late-stage trial for KSI-301 as a possible therapy for treatment-naïve retinal vein occlusion.
For further details see:
Why Kodiak Sciences Stock Is Sharply Lower Today